Arabic Arabic English English French French German German
dark

COVID-19 ‘cocktail’ therapy moves to clinical trial

COVID-19 ‘cocktail’ therapy moves to clinical trial
tjordan_drupal
Jun 26, 2020

A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.

The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.

Novel Coronavirus (COVID-19)

Headline
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by HFACULTY News. Publisher: News Feed Click this link to read the full content from the Publisher Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AMA releases CPT code for antigen tests

Next Post

Nearly 487,000 enroll in HealthCare.gov coverage in April

Related Posts
Total
0
Share